Shanghai Pioneer Holding (HKSE:01345) Research & Development: HK$3 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01345 Shanghai Pioneer Holding Ltd HKSE:01345
73 GF Score
Price HK$2.25
GF Value HK$1.80
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Shanghai Pioneer Holding Research & Development?

Shanghai Pioneer Holding HKSE:01345 -1.75% 73 Research & Development is HK$3 Mil as of Dec. 2025. GuruFocus rates HKSE:01345 with a GF Score™ of 73/100 and a GF Value™ of HK$1.80 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Pioneer Holding's Research & Development for the six months ended in Dec. 2025 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$3 Mil.

Shanghai Pioneer Holding  (HKSE:01345) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Pioneer Holding Research & Development Related Terms

Shanghai Pioneer Holding Research & Development Historical Data

* Premium members only.

The historical data trend for Shanghai Pioneer Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Pioneer Holding Research & Development Chart

Shanghai Pioneer Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shanghai Pioneer Holding Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.65 0.00 2.60 0.00
HKSE:01345
73GF Score
Shanghai Pioneer Holding Ltd HKSE:01345
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Pioneer Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$3 Mil mean?
Shanghai Pioneer Holding (HKSE:01345) has a Research & Development of HK$3 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Pioneer Holding and its competitors.
Is Shanghai Pioneer Holding's Research & Development too high?
Shanghai Pioneer Holding's current Research & Development is HK$3 Mil. Overall, Shanghai Pioneer Holding has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pioneer Holding's Research & Development compare to competitors?
Shanghai Pioneer Holding's Research & Development of HK$3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Pioneer Holding and its competitors. Shanghai Pioneer Holding's current Research & Development is HK$3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pioneer Holding stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pioneer Holding (HKSE:01345) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.80, compared to a current price of HK$2.25 — trading 25% above its estimated fair value. The current Research & Development is HK$3 Mil. Shanghai Pioneer Holding's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shanghai Pioneer Holding (HKSE:01345), the current Research & Development is HK$3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Pioneer Holding (HKSE:01345) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pioneer Holding stock appears to be overvalued. The current stock price of HK$2.25 is trading 25% above its estimated GF Value™ of HK$1.80. GuruFocus considers Shanghai Pioneer Holding to be Modestly Overvalued.

Key valuation signals for HKSE:01345:

  • Research & Development: HK$3 Mil
  • GF Value™: HK$1.80 vs. price of HK$2.25 (25% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the HKSE:01345 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Pioneer Holding Business Description

Address No.15, Lane 88 Wuwei Road, Putuo District, Shanghai, CHN, 200331
Shanghai Pioneer Holding Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the marketing, promotion, sales, and channel management service for imported pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, odontology, cardiology and wound care products. The majority of its revenue derives from the Sales of medical equipment and supplies. The group operates mainly in the People's Republic of China.
73GF Score

Get the complete analysis for HKSE:01345

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.25
Price
HK$1.80
GF Value